in vivo ≠ in vitro [Power / Sample Size]

posted by dshah  – India/United Kingdom, 2022-07-25 13:19 (584 d 09:55 ago) – Posting: # 23171
Views: 1,691

Hi Mithu!

❝ Here the case is, we are dealing with some technology transfer products in which we could not change our test formulation which was meet the BE marginally at the time of initially filing. now due to this bottle neck, our thinking is if we take little large sample size, than we can manage variability (my expectation may be not correct).

As per regulatory acceptance- it is either acceptable or unacceptable. So is not best to describe it as marginally acceptable.

The in vitro assessment with recent batches of reference is important and also performing a comparative dissolution with older lot (if still available) can be useful.

Taking only larger size without consideration of in vitro assessment will not solve your problem.

Divyen Shah

Complete thread:

UA Flag
 Admin contact
22,916 posts in 4,807 threads, 1,646 registered users;
31 visitors (0 registered, 31 guests [including 6 identified bots]).
Forum time: 22:15 CET (Europe/Vienna)

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz